Treatment of myxoedema coma--factors associated with fatal outcome.

Treatment of myxoedema coma has been associated with a high mortality. The causes of death were analysed in this paper by retrospective study of the records of 11 myxoedema coma patients. The serum thyroxine (T4) and triiodothyronine (T3) levels were estimated retrospectively from the amounts of hormone given to the patients by a two-compartment model. Seven patients died and 4 survived. The patients who died were significantly older (78.9 +/- 2.2 years, mean +/- SEM) than those who survived (66.8 +/- 3.7 years). The initial heart rate was lower in the decreased group, but both groups had increased their heart rate on treatment. The surviving patients showed an increase in body temperature during the first 3 days of treatment, in contrast to the patients who eventually died. The deceased patients had received larger amounts of thyroid hormone and had calculated levels of T3 that were nearly twice as high as those of the surviving patients. Old age and a high serum level of T3 are determinants for the fatal outcome of myxoedema coma. Our analysis underscores the importance of using a cautious replacement regimen in myxoedema coma patients.

[1]  U. Rosenqvist,et al.  Peripheral responses to thyroxine in hypothyroid subjects as a function of dose and duration of substitution. , 2009, Acta medica Scandinavica.

[2]  U. Rosenqvist,et al.  The cardiovascular response at rest and during exercise in hypothyroid subjects to thyroxine substitution , 1983, Clinical cardiology.

[3]  J. M. Lanao,et al.  Thyroxine and Triiodothyronine Kinetics and Extrathyroidal Peripheral Conversion Rate of Thyroxine to Triiodothyronine in Healthy Elderly Humans , 1981, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[4]  A. Khaleeli.  Myxoedema coma. A report on five successfully treated cases , 1978 .

[5]  G. Holmes,et al.  Myxoedema coma presenting in status epilepticus. , 1977, Postgraduate medical journal.

[6]  P. Suter,et al.  REDUCED ACTIVE THYROID HORMONE LEVELS IN ACUTE ILLNESS , 1976, The Lancet.

[7]  W. B. Hunt,et al.  Is myxedema coma respiratory failure? , 1976, Southern medical journal.

[8]  D. Solomon,et al.  Reciprocal Changes in Serum Concentrations of 3,3′,5′-Triiodothyronine (Reverse T3) and 3,3′5-Triiodothyronine (T3) in Systemic Illnesses , 1975 .

[9]  L. Braverman,et al.  Active form of the thyroid hormone. , 1975, Annual review of medicine.

[10]  M. Surks,et al.  Determination of iodothyronine absorption and conversion of L-thyroxine (T 4 ) to L-triiodothyronine (T 3 ) using turnover rate techniques. , 1973, The Journal of clinical investigation.

[11]  M. Surks,et al.  Propylthiouracil inhibits the conversion of L-thyroxine to L-triiodothyronine. An explanation of the antithyroxine effect of propylthiouracil and evidence supporting the concept that triiodothyronine is the active thyroid hormone. , 1972, The Journal of clinical investigation.

[12]  M. Runták,et al.  [Coma in myxedema]. , 1970, Vnitrni lekarstvi.

[13]  W. Green.  Guidelines for the treatment of myxedema. , 1968, The Medical clinics of North America.

[14]  I. Copperman.  Myxoedema coma due to de Quervain's granulomatous thyroiditis--a case report. , 1968, Journal of the Irish Medical Association.

[15]  C. J. Goodner,et al.  TREATMENT OF MYXEDEMA COMA WITH INTRAVENOUS THYROXINE. , 1964, Archives of internal medicine.

[16]  S. Russell,et al.  Myxedema, shock and coma. Seven survival cases. , 1961, Archives of internal medicine.

[17]  J. Nickerson,et al.  Fatal myxedema, with and without coma. , 1960, Annals of internal medicine.

[18]  J. Kelly,et al.  Myxedema coma. , 1959, Annals of internal medicine.